| Variable | n (%) | Mean ± SD | 95% CI | Min | Max | Median |
| HbA1c at baseline (mmol/mol) | 300 (100%) | 72.4 ± 10.3 | 71.2 - 73.5 | 61.0 | 121.0 | 69.5 |
| HbA1c at baseline (% DCCT) | 300 (100%) | 8.8 ± 0.9 | 8.7 - 8.9 | 7.7 | 13.2 | 8.5 |
| HbA1c at month 6 (mmol/mol)* | 289 (96.3%) | 62.5 ± 11.8 | 61.1 - 63.9 | 30.0 | 115.0 | 60.0 |
| HbA1c at month 6 (% DCCT)* | 289 (96.3%) | 7.9 ± 1.1 | 7.7 - 8.0 | 4.9 | 12.7 | 7.6 |
| HbA1c < 53 mmol/mol at month 6 | 51 (17.6%) | 49.1 ± 3.7 | 48.1 - 50.2 | 30.0 | 52.0 | 50.0 |
| HbA1c ≥ 53 mmol/mol at month 6 | 238 (82.4%) | 65.4 ± 11.0 | 64.0 - 66.8 | 53.0 | 115.0 | 62.0 |
| HbA1c < 7% at month 6 | 51 (17.6%) | 6.7 ± 0.3 | 6.6 - 6.7 | 4.9 | 6.9 | 6.7 |
| HbA1c ≥ 7% at month 6 | 238 (82.4%) | 8.1 ± 1.0 | 8.0 - 8.3 | 7.0 | 12.7 | 7.8 |
| HbA1c decrease of at least 0.5% at month 6 | 191(66.1%) | 7.5 ± 0.8 | 7.3 - 7.6 | 4.9 | 12.7 | 7.3 |
| HbA1c decrease of less than 0.5% at month 6 | 98 (33.9%) | 8.7 ± 1.1 | 8.5 - 8.9 | 7.4 | 12.1 | 8.5 |
| FPG at baseline (mmol/L) | 300 (100%) | 9.3 ± 2.8 | 8.9 - 9.6 | 3.0 | 22.4 | 8.9 |
| FPG at month 3 (mmol/L) | 295 (98.3%) | 7.8 ± 2.3 | 7.5 - 8.1 | 3.8 | 20.1 | 7.3 |
| FPG at month 6 (mmol/L) | 289 (96.3%) | 7.5 ± 2.1 | 7.3 - 7.8 | 3.9 | 15.7 | 7.1 |
| Dose of Gla-300 at baseline (U/day) | 300 (100%) | 27.1 ± 12.2 | 25.7 - 28.5 | 8 | 80 | 24.0 |
| Dose of Gla-300 at month 3 (U/day) | 295 (98.3%) | 30.9 ± 12.9 | 29.4 - 32.4 | 8 | 84 | 28.0 |
| Dose of Gla-300 at month 6 (U/day) | 289 (96.3%) | 33.7 ± 13.8 | 32.1 - 35.3 | 8 | 80 | 32.0 |
| Dose of Gla-300 at baseline (U/kg/day) | 300 (100%) | 0.29 ± 0.12 | 0.27 - 0.30 | 0.07 | 0.82 | 0.27 |
| Dose of Gla-300 at month 3 (U/kg/day) | 295 (98.3%) | 0.33 ± 0.13 | 0.31 - 0.34 | 0.08 | 0.84 | 0.31 |
| Dose of Gla-300 at month 6 (U/kg/day) | 289 (96.3%) | 0.36 ± 0.14 | 0.34 - 0.37 | 0.08 | 0.91 | 0.34 |